Agilent Credits Strong Performance of 1200 Infinity Product Line for 25 Percent Growth in Q3 LC Sales
August 20, 2010
Agilent Credits Strong Performance of 1200 Infinity Product Line for 25 Percent Growth in Q3 LC Sales
CEO Bill Sullivan cited the 1290 Infinity LC and the recently introduced 1260 Infinity and 1220 Infinity platforms as drivers of the company's liquid chromatography business.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Agilent Posts 35 Percent Jump in Q4 Revenue, Strong Sales of Infinity LC
November 12, 2010 / ProteoMonitor - New LC Releases Emphasize Cross-Platform Compatibility, Bio-Inert Capabilities
June 25, 2010 / ProteoMonitor - Instrument Vendors Focus on UPLC and Triple-Quad, Qual-Quan MS at JP Morgan Conference
January 14, 2011 / ProteoMonitor - Proteomics Expectations Bear Fruit in 2010, But Challenges Remain
January 7, 2011 / ProteoMonitor - Waters Says Switching to UHPLC Could Trigger Significant Growth In Instrument Business
October 29, 2010 / ProteoMonitor